Contents

Search


budesonide/formoterol (Symbicort)

Indications: - asthma & reactive airway disease, maintenace therapy - maintenance therapy for COPD (2nd line therapy) Dosage: - 2 puffs BID - use 160/4.5 for COPD [3] Inhalation: 80/4.5 & 160/4.5 mg budesonide/mg formoterol Storage: good for 90 days after opening [4] Adverse effects: - oral candidiasis - dysphonia - bronchitis - headache - muscle spasms Notes: Manufacturer: AstraZeneca

General

LABA glucocorticoid combination

References

  1. Prescriber's Letter 14(2): 2007 New drugs approved by the FDA in 2006 Detail-Document#: 2302213 (subscription needed) http://www.prescribersletter.com
  2. Prescriber's Letter 14(8): 2007 Symbicort (Budesonide/Formoterol) Inhalation Aerosol Detail-Document#: 230812 (subscription needed) http://www.prescribersletter.com
  3. Prescriber's Letter 16(4): 2009 Symbicort (Budesonide/Formoterol) for COPD Detail-Document#: 250126 (subscription needed) http://www.prescribersletter.com
  4. Prescriber's Letter 16(9): 2009 COMMENTARY: Shortened Expiration Dating of Some Inhalation Products PATIENT HANDOUT: Tips for Correct Use of Inhalers Detail-Document#: 250903 (subscription needed) http://www.prescribersletter.com

Components

budesonide (Rhinocort, Pulmicort, Turbuhaler, Flexhaler, Entocort EC, Uceris, Cortiment, Eohilia) formoterol (Foradil, Perforomist)